



## Prenetics Reports Record First Quarter 2022 Preliminary Financial Results. Nasdaq Listing in Partnership with Artisan Acquisition Corp. Expected on May 18, 2022<sup>1</sup>

May 4, 2022

*Continues to Deliver Strong Results and Significant Growth*

### First Quarter 2022 Highlights

- **Revenue** for the first quarter of 2022 was US\$92.0 million, a record high, compared to US\$57.5 million in the first quarter of 2021
- **(Loss)/profit from operations** under IFRS was US\$(0.6) million in the first quarter of 2022, compared to US\$11.1 million in the first quarter of 2021. **Adjusted EBITDA (non-IFRS)<sup>(2)</sup>** was US\$12.7 million compared to US\$12.5 million in the first quarter of 2021
- Potential acquisition targets being identified in the telehealth and personalized care sectors in Southeast Asia and in Europe
- Performed and delivered more than 22 million COVID-19 laboratory and rapid at-home tests globally to date
- Registration Statement for proposed business combination with Artisan Acquisition Corp. declared effective by the SEC, with Nasdaq listing expected on May 18, 2022, subject to satisfaction or waiver of the conditions

**LONDON and HONG KONG, May 4, 2022** – Prenetics Group Limited ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, today announced its preliminary unaudited financial results for the first quarter of 2022. Prenetics continued to deliver significant revenue growth, driven by strong demand for its diagnostics and genetic testing services.

"Our record performance in the first quarter, in both revenues and adjusted EBITDA, firmly demonstrates the robust demand for our testing services and strength of our technology. We are confident in sustaining the growth momentum as we continue to launch new innovative products and execute on our global M&A strategy in the coming quarters. With our strong balance sheet of US\$93.4 million in cash and trade receivables and the expected listing on Nasdaq, we are in advanced M&A discussions with multiple companies in Europe and Southeast Asia in the areas of telehealth and personalized care, which we believe can add additional revenues and new technology to our portfolio," said **Danny Yeung, CEO & Co-founder of Prenetics**.

He continued, "We are pleased with the progress made towards our Nasdaq Listing. We received the declaration of effectiveness of the Registration Statement from the SEC and expect to be listed on Nasdaq under the ticker symbol "PRE" on May 18, 2022, subject to satisfaction or waiver of the conditions. This is a significant milestone for Prenetics and for Artisan Acquisition Corp. and we are ready to take to the global stage our mission to decentralize healthcare by bringing it closer to millions of patients globally."

The Company has a robust product pipeline and is launching a range of new products in the first half of 2022, including ColoClear, a non-invasive stool-based FIT-DNA test for colorectal cancer screening, and Circle Snapshot, an at-home blood test with a user-friendly blood sample collection and result delivery system.

<sup>1</sup> Subject to satisfaction or waiver of the conditions.

<sup>2</sup> Adjusted EBITDA (non-IFRS) represents (loss)/profit from operations under IFRS before equity-settled share-based payment expenses, depreciation and amortization, other strategic financing, transactional expense and non-operating expense, and finance income, exchange gain or loss. See the section titled "Unaudited Financial Information and Non-IFRS Financial Measures" and the table captioned "Reconciliation of (Loss)/profit from Operations under IFRS and Adjusted EBITDA (Non-IFRS)" set forth in this document.

### Preliminary Financial Highlights for the Three Months ended March 31, 2022

*For the three months ended March 31, 2022*

2022	2021	Y-o-Y change
(unaudited)	(unaudited)	
(in US\$ millions, except percentages)		

### Financial metrics

Revenue	92.0	57.5	60.2%
Gross Profit	36.0	21.9	64.3%
(Loss)/profit from operations under IFRS	(0.6)	11.1	-105.0%
Adjusted EBITDA (Non-IFRS) <sup>(1)</sup>	12.7	12.5	1.4%

	As of March 31, 2022	As of December 31, 2021	Q-o-Q change
Trade receivables	59.2	47.0	26.0%
Cash and cash equivalents	34.2	35.3	-3.0%

Note:

(1) Adjusted EBITDA (non-IFRS) represents (loss)/profit from operations under IFRS before equity-settled share-based payment expenses, depreciation and amortization, other strategic financing, transactional expense and non-operating expense, and finance income, exchange gain or loss. See the section titled "Unaudited Financial Information and Non-IFRS Financial Measures" and the table captioned "Reconciliation of (Loss)/profit from Operations under IFRS and Adjusted EBITDA (Non-IFRS)" set forth in this document.

- Revenue reached a record quarter high of US\$92.0 million, an increase of 60.2% from US\$57.5 million in the same period in 2021. This uplift was driven by strong demand for its diagnostics and genetic testing services.
  - Prenetics has performed and delivered more than 22 million laboratory tests and at-home tests globally to date.
- Gross profit was US\$36.0 million, an increase of 64.3%, from US\$21.9 million in the same period in 2021. Gross margin increased from 38.2% for the three months ended March 31, 2021 to 39.2% for the three months ended March 31, 2022, due to improved cost management in diagnostic testing services.
- Loss from operations was US\$0.6 million, compared to profit from operations of US\$11.1 million in the same period in 2021. The loss was primarily due to increase of non-cash share-based payment associated with an increase in the equity value of the Company.
- Adjusted EBITDA (non-IFRS) was US\$12.7 million, an increase of 1.4% from US\$12.5 million in the same period in 2021, due to increased operating efficiencies and scalability of the business.
- As of March 31, 2022, the Company had cash and trade receivables of US\$93.4 million, consisting of US\$34.2 million of cash and US\$59.2 million of trade receivables.

## About Prenetics

Founded in 2014, Prenetics is a major global diagnostics and genetic testing company with the mission to bring health closer to millions of people globally and decentralize healthcare by making the three pillars — Prevention, Diagnostics and Personalized Care — comprehensive and accessible to anyone, at anytime and anywhere. Prenetics is led by visionary entrepreneur, Danny Yeung, with operations across 9 locations, including United Kingdom, Hong Kong, India, South Africa, and Southeast Asia. Prenetics develops consumer genetic testing and early colorectal cancer screening; provides COVID-19 testing, rapid point of care and at-home diagnostic testing and medical genetic testing. To learn more about Prenetics, visit [www.prenetics.com](http://www.prenetics.com).

### ENQUIRIES:

#### For Prenetics:

##### Investors:

Sabrina Chan

[sabrina.chan@prenetics.com](mailto:sabrina.chan@prenetics.com)

##### Media:

Finsbury Glover Hering

Richard Barton +852 9301 2056

Harry Florry +852 9818 2239

Nicolas Mo +852 6019 9877

[Prenetics-HKG@finsbury.com](mailto:Prenetics-HKG@finsbury.com)

## Forward-Looking Statements

This document contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act that are based on beliefs and assumptions and on information currently available to Artisan and Prenetics, and also contains certain financial forecasts and projections.

All statements other than statements of historical fact contained in this document, including, but not limited to, statements as to future results of operations and financial position, Prenetics' plans for new product development and geographic expansion, objectives of management for future operations of Prenetics, projections of market opportunity and revenue growth, competitive position, technological and market trends, anticipated benefits of the proposed transaction and expectations related to the terms of the proposed transaction, are also forward-looking statements. In some cases, you can identify forward-looking statements by the following words: "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing," "target," "seek" or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. These statements are based upon estimates and forecasts and reflect the views, assumptions, expectations, and opinions of Artisan and Prenetics, which involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Any such estimates, assumptions, expectations, forecasts, views or opinions, whether or not identified in this document, should be regarded as indicative, preliminary and for illustrative purposes only and should not be relied upon as being necessarily indicative of future results. Although each of Artisan, Prenetics and PubCo believes that it has a reasonable basis for each forward-looking statement contained in this document, each of Artisan, Prenetics and PubCo caution you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of PubCo's registration statement on Form F-4, the proxy statement/ prospectus therein, and other documents filed by Artisan or PubCo from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those expressed or implied in the forward-looking statements. Neither Artisan, Prenetics nor PubCo can assure you that the forward-looking statements in this document will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including the ability to complete the business combination due to the failure to obtain approval from Artisan's shareholders or satisfy other closing conditions in the business combination agreement, the occurrence of any event that could give rise to the termination of the business combination agreement, the ability to recognize the anticipated benefits of the business combination, the amount of redemption requests made by Artisan's public shareholders, costs related to the transaction, the impact of the global COVID-19 pandemic, the risk that the transaction disrupts current plans and operations as a result of the announcement and consummation of the transaction, the outcome of any potential litigation, government or regulatory proceedings and other risks and uncertainties, including those included under the heading "Risk Factors" in the registration statement on Form F-4 filed by PubCo with the SEC and those included under the heading "Risk Factors" in the final prospectus of Artisan dated May 13, 2021 and in its subsequent quarterly reports on Form 10-Q and other filings with the SEC. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by Artisan, Prenetics, PubCo, their respective directors, officers or employees or any other person that Artisan, Prenetics or PubCo will achieve their objectives and plans in any specified time frame, or at all. The forward-looking statements in this document represent the views of Artisan, Prenetics and PubCo as of the date of this document. Subsequent events and developments may cause those views to change. However, while Artisan, Prenetics and PubCo may update these forward-looking statements in the future, Artisan, Prenetics and PubCo specifically disclaim any obligation to do so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of Artisan, Prenetics or PubCo as of any date subsequent to the date of this document. Accordingly, undue reliance should not be placed upon the forward-looking statements.

## Unaudited Financial Information and Non-IFRS Financial Measures

To supplement Prenetics' consolidated financial statements prepared in accordance with International Financial Reporting Standards ("IFRS"), the Company is providing non-IFRS measure, Adjusted EBITDA. This non-IFRS financial measure is not based on any standardized methodology prescribed by IFRS and is not necessarily comparable to similarly-titled measures presented by other companies. Management believes this non-IFRS financial measure is useful to investors in evaluating the Company's ongoing operating results and trends.

Management is excluding from some or all of its non-IFRS operating results (1) Equity-settled share-based payment expenses, (2) depreciation and amortization, (3) finance income and exchange gain or loss, and (4) other discretionary items determined by management. These non-IFRS financial measures are limited in value because they exclude certain items that may have a material impact on the reported financial results. Management accounts for this limitation by analyzing results on a IFRS basis as well as a non-IFRS basis and also by providing IFRS measures in the Company's public disclosures.

In addition, other companies, including companies in the same industry, may not use the same non-IFRS measures or may calculate these metrics in a different manner than management or may use other financial measures to evaluate their performance, all of which could reduce the usefulness of these non-IFRS measures as comparative measures. Because of these limitations, the Company's non-IFRS financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with IFRS. Investors are encouraged to review the non-IFRS reconciliations provided in the tables below. As noted elsewhere, certain IFRS results are preliminary and subject to change.

Reconciliation of (Loss)/profit from Operations under IFRS and Adjusted EBITDA (Non-IFRS)

<i>For the three months ended March 31</i>	<b>2022</b>	<b>2021</b>
	(unaudited)	(unaudited)
	<b>(in US\$ millions)</b>	
(Loss)/profit from operations under IFRS	(0.6)	11.1

Equity-settled share-based payment expenses	9.4	0.2
Depreciation and amortization	2.2	1.1
Other strategic financing, transactional expense and non-operating expense	1.7	0.5
Finance income, exchange gain or loss	-	(0.4)
<b>Adjusted EBITDA (Non-IFRS)</b>	<b>12.7</b>	<b>12.5</b>